APVO

$0.00

(

0.00%

) Quote details
Add to Watchlist Run Backtest
stock

Aptevo Therapeutics Inc

NASDAQ | APVO

1.41

USD

$0.00

(

0.00%

)

At Close (As of Nov 4, 2025)

$20.30M

Market Cap

0.0005

P/E Ratio

2680.54

EPS

$265.81

52 Week High

$1.32

52 Week Low

HEALTHCARE

Sector

APVO Chart

Recent Chart
Price Action

APVO Technicals

Tags:

APVO Earnings

Yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$352K
Total Revenue $0
Cost Of Revenue $352K
Costof Goods And Services Sold $352K
Operating Income -$25M
Selling General And Administrative $10M
Research And Development $14M
Operating Expenses $24M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $352K
Income Before Tax -$24M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$24M
Comprehensive Income Net Of Tax -
Ebit -$24M
Ebitda -$24M
Net Income -$24M

Revenue & Profitability

Earnings Performance

APVO Financials

yearly Balance Sheet (As of Dec 31, 2024)

Field Value (USD)
Total Assets $16M
Total Current Assets $11M
Cash And Cash Equivalents At Carrying Value $8.7M
Cash And Short Term Investments $8.7M
Inventory -
Current Net Receivables -
Total Non Current Assets $4.9M
Property Plant Equipment -
Accumulated Depreciation Amortization Ppe -
Intangible Assets -
Intangible Assets Excluding Goodwill -
Goodwill -
Investments -
Long Term Investments -
Short Term Investments -
Other Current Assets $1.9M
Other Non Current Assets -
Total Liabilities $11M
Total Current Liabilities $6.2M
Current Accounts Payable $3.1M
Deferred Revenue -
Current Debt -
Short Term Debt -
Total Non Current Liabilities $4.6M
Capital Lease Obligations $4.6M
Long Term Debt -
Current Long Term Debt -
Long Term Debt Noncurrent -
Short Long Term Debt Total $4.6M
Other Current Liabilities $3.2M
Other Non Current Liabilities -
Total Shareholder Equity $4.8M
Treasury Stock -
Retained Earnings -$248M
Common Stock $84K
Common Stock Shares Outstanding $14K

yearly Cash Flow (As of Dec 31, 2024)

Field Value (USD)
Operating Cashflow -$24M
Payments For Operating Activities -
Proceeds From Operating Activities -
Change In Operating Liabilities -
Change In Operating Assets -
Depreciation Depletion And Amortization $352K
Capital Expenditures $0
Change In Receivables -
Change In Inventory -
Profit Loss -
Cashflow From Investment -
Cashflow From Financing $16M
Proceeds From Repayments Of Short Term Debt -
Payments For Repurchase Of Common Stock -
Payments For Repurchase Of Equity -
Payments For Repurchase Of Preferred Stock -
Dividend Payout -
Dividend Payout Common Stock -
Dividend Payout Preferred Stock -
Proceeds From Issuance Of Common Stock -
Proceeds From Issuance Of Long Term Debt And Capital Securities Net -
Proceeds From Issuance Of Preferred Stock -
Proceeds From Repurchase Of Equity -
Proceeds From Sale Of Treasury Stock -
Change In Cash And Cash Equivalents -
Change In Exchange Rate -
Net Income -$24M

yearly Income Statement (As of Dec 31, 2024)

Field Value (USD)
Gross Profit -$352K
Total Revenue $0
Cost Of Revenue $352K
Costof Goods And Services Sold $352K
Operating Income -$25M
Selling General And Administrative $10M
Research And Development $14M
Operating Expenses $24M
Investment Income Net -
Net Interest Income -
Interest Income -
Interest Expense -
Non Interest Income -
Other Non Operating Income -
Depreciation -
Depreciation And Amortization $352K
Income Before Tax -$24M
Income Tax Expense -
Interest And Debt Expense -
Net Income From Continuing Operations -$24M
Comprehensive Income Net Of Tax -
Ebit -$24M
Ebitda -$24M
Net Income -$24M

APVO News

APVO Profile

Aptevo Therapeutics Inc Profile

Sector: HEALTHCARE

Industry: BIOTECHNOLOGY

Aptevo Therapeutics Inc. is a Seattle-based clinical-stage biotechnology firm committed to pioneering immunotherapeutic solutions for various oncology indications. Leveraging its proprietary platform technologies, the company develops next-generation therapies aimed at improving patient outcomes in cancer treatment. With a strong emphasis on innovation, Aptevo boasts a robust pipeline that positions it for meaningful advancements in the biopharmaceutical sector, offering significant potential for growth and impact in the rapidly evolving landscape of cancer therapies.

PTLE
+51.53%
$0.28
MSPR
+27.56%
$0.66
SCNX
+15.35%
$0.81
NVDA
-3.95%
$198.69
ORIS
-0.12%
$0.16
BYND
-4.31%
$1.33
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
HTZ
+36.23%
$6.73
PLTR
-7.93%
$190.74
ASST
-1.57%
$1.25
GRAB
-4.69%
$5.78
INTC
-6.25%
$37.03
PLUG
-8.36%
$2.52
ONDS
-3.08%
$5.96
CHR
+8.10%
$0.13
WTO
-6.22%
$0.04
DNN
-6.16%
$2.74
TSLA
-5.14%
$444.26
CAPT
+31.77%
$0.66
NFE
+14.40%
$1.35
ETHD
+20.91%
$5.26
BITF
-6.56%
$3.84
EPWK
+3.60%
$0.07
T
-0.36%
$24.44
SOFI
-4.11%
$29.37
F
-1.69%
$12.79
AXDX
-61.36%
$0.03
CIFR
-1.09%
$22.51
GPUS
-7.02%
$0.34
HIMS
-3.60%
$42.79
CMBM
+58.82%
$3.24
BTBT
-7.01%
$3.18
NCLH
-15.28%
$18.79
BURU
-7.90%
$0.28
AAL
-5.17%
$12.65
AMD
-3.69%
$250.05
RGTI
-10.07%
$35.18
RIVN
-5.23%
$12.50
BTG
-5.88%
$4.00
MARA
-6.68%
$16.62
AMZN
-1.84%
$249.32
VALE
-2.13%
$11.94
ADAP
-15.14%
$0.05
AAPL
+0.36%
$270.04
UBER
-5.06%
$94.67
PLTZ
+16.06%
$6.07
SOUN
-11.57%
$15.13
BAC
-0.03%
$53.54
BMNR
-7.93%
$39.46
SNAP
-4.47%
$7.47
WULF
-6.77%
$15.01
RXRX
-8.08%
$5.00
VSEE
+3.03%
$1.02
NIO
-3.50%
$7.16
NGD
-8.79%
$6.64
WBD
+1.39%
$22.60
RUBI
-11.62%
$0.60
CCL
-9.05%
$26.11
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
ADD
-25.47%
$0.05
SMCI
-6.60%
$47.40
NVTS
-14.61%
$10.46
RIG
-1.51%
$3.90
QBTS
-10.12%
$29.74
SMX
+40.80%
$2.06
PLTD
+7.99%
$6.35
HPE
-3.83%
$23.56
SRM
+53.27%
$10.30
CMG
+0.72%
$31.74
VZ
-0.38%
$39.32
DVLT
-3.26%
$1.78
LUMN
-10.90%
$10.54
AMCR
+0.12%
$7.87
KDLY
-11.88%
$0.78
NAKA
-11.88%
$0.78
KEY
-1.31%
$17.30
GOOGL
-2.17%
$277.54
IONZ
+17.01%
$4.47
CLF
-10.02%
$10.68
UUUU
-4.43%
$17.01
APLD
-5.50%
$31.06
NVO
-1.75%
$48.25
WLGS
-5.57%
$0.04
CLSK
-6.88%
$16.22
AGNC
+1.29%
$10.18
RR
-8.78%
$4.05
CGC
-5.83%
$1.12
DENN
+50.36%
$6.18
CTRA
+5.98%
$25.85
FUBO
+6.35%
$3.68
RANI
+10.69%
$2.38
ETWO
0.00%
$3.30
HOOD
-6.98%
$136.80
BBD
-1.15%
$3.41
PCG
+1.57%
$16.16
QS
-4.75%
$15.44
MSAI
-32.32%
$1.34
AUR
-11.18%
$4.48
PTLE
+51.53%
$0.28
MSPR
+27.56%
$0.66
SCNX
+15.35%
$0.81
NVDA
-3.95%
$198.69
ORIS
-0.12%
$0.16
BYND
-4.31%
$1.33
PFE
-1.45%
$24.30
VHAI
0.00%
$0.00
HTZ
+36.23%
$6.73
PLTR
-7.93%
$190.74
ASST
-1.57%
$1.25
GRAB
-4.69%
$5.78
INTC
-6.25%
$37.03
PLUG
-8.36%
$2.52
ONDS
-3.08%
$5.96
CHR
+8.10%
$0.13
WTO
-6.22%
$0.04
DNN
-6.16%
$2.74
TSLA
-5.14%
$444.26
CAPT
+31.77%
$0.66
NFE
+14.40%
$1.35
ETHD
+20.91%
$5.26
BITF
-6.56%
$3.84
EPWK
+3.60%
$0.07
T
-0.36%
$24.44
SOFI
-4.11%
$29.37
F
-1.69%
$12.79
AXDX
-61.36%
$0.03
CIFR
-1.09%
$22.51
GPUS
-7.02%
$0.34
HIMS
-3.60%
$42.79
CMBM
+58.82%
$3.24
BTBT
-7.01%
$3.18
NCLH
-15.28%
$18.79
BURU
-7.90%
$0.28
AAL
-5.17%
$12.65
AMD
-3.69%
$250.05
RGTI
-10.07%
$35.18
RIVN
-5.23%
$12.50
BTG
-5.88%
$4.00
MARA
-6.68%
$16.62
AMZN
-1.84%
$249.32
VALE
-2.13%
$11.94
ADAP
-15.14%
$0.05
AAPL
+0.36%
$270.04
UBER
-5.06%
$94.67
PLTZ
+16.06%
$6.07
SOUN
-11.57%
$15.13
BAC
-0.03%
$53.54
BMNR
-7.93%
$39.46
SNAP
-4.47%
$7.47
WULF
-6.77%
$15.01
RXRX
-8.08%
$5.00
VSEE
+3.03%
$1.02
NIO
-3.50%
$7.16
NGD
-8.79%
$6.64
WBD
+1.39%
$22.60
RUBI
-11.62%
$0.60
CCL
-9.05%
$26.11
RMBL
+60.50%
$3.21
JOBY
-9.55%
$14.76
ADD
-25.47%
$0.05
SMCI
-6.60%
$47.40
NVTS
-14.61%
$10.46
RIG
-1.51%
$3.90
QBTS
-10.12%
$29.74
SMX
+40.80%
$2.06
PLTD
+7.99%
$6.35
HPE
-3.83%
$23.56
SRM
+53.27%
$10.30
CMG
+0.72%
$31.74
VZ
-0.38%
$39.32
DVLT
-3.26%
$1.78
LUMN
-10.90%
$10.54
AMCR
+0.12%
$7.87
KDLY
-11.88%
$0.78
NAKA
-11.88%
$0.78
KEY
-1.31%
$17.30
GOOGL
-2.17%
$277.54
IONZ
+17.01%
$4.47
CLF
-10.02%
$10.68
UUUU
-4.43%
$17.01
APLD
-5.50%
$31.06
NVO
-1.75%
$48.25
WLGS
-5.57%
$0.04
CLSK
-6.88%
$16.22
AGNC
+1.29%
$10.18
RR
-8.78%
$4.05
CGC
-5.83%
$1.12
DENN
+50.36%
$6.18
CTRA
+5.98%
$25.85
FUBO
+6.35%
$3.68
RANI
+10.69%
$2.38
ETWO
0.00%
$3.30
HOOD
-6.98%
$136.80
BBD
-1.15%
$3.41
PCG
+1.57%
$16.16
QS
-4.75%
$15.44
MSAI
-32.32%
$1.34
AUR
-11.18%
$4.48
2025 © AfterPullback LTD

Charts powered by TradingView

Market data may be delayed by 15 minutes or more and is provided by financial exchanges or third-party providers. AfterPullback does not verify or guarantee its accuracy and assumes no responsibility to do so. This website is not operated by a licensed attorney, accountant, or financial advisor. Nothing on this site constitutes financial advice or replaces consultation with a qualified professional who understands your specific circumstances. Always consult a licensed financial advisor before making investment decisions.